Float Short %

14.74

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

0.01

EPS Last/This Y

0.05

EPS This/Next Y

0.43

Price

11.95

Target Price

23.56

Analyst Recom

1.2

Performance Q

64.6

Relative Volume

1.09

Beta

-1.27

Ticker: DAWN

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	DAWN	9.45	0.21	6.59	51101
2025-12-29	DAWN	9.38	0.22	0.95	51546
2025-12-30	DAWN	9.18	0.22	2.07	51583
2025-12-31	DAWN	9.32	0.22	0.23	51608
2026-01-02	DAWN	8.85	0.22	3.49	51837
2026-01-05	DAWN	8.54	0.23	0.51	52813
2026-01-06	DAWN	8.63	0.24	0.49	53793
2026-01-07	DAWN	9.62	0.25	0.04	55056
2026-01-08	DAWN	9.25	0.24	0.47	57726
2026-01-09	DAWN	8.94	0.24	1.19	58264
2026-01-12	DAWN	11.32	0.25	0.70	58720
2026-01-13	DAWN	10.59	0.35	0.34	61812
2026-01-14	DAWN	10.72	0.40	0.48	62986
2026-01-15	DAWN	10.49	0.41	0.01	63357
2026-01-16	DAWN	10.13	0.47	0.13	57937
2026-01-20	DAWN	12.12	0.96	0.08	19688
2026-01-21	DAWN	12.06	0.33	0.75	47098
2026-01-22	DAWN	12.32	0.37	0.04	52598
2026-01-23	DAWN	11.95	0.38	0.17	51905
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	DAWN	9.44	68.1	-	-0.97
2025-12-29	DAWN	9.38	68.1	-	-0.97
2025-12-30	DAWN	9.18	68.1	-	-0.97
2025-12-31	DAWN	9.32	68.1	-	-0.97
2026-01-02	DAWN	8.85	68.1	-	-0.97
2026-01-05	DAWN	8.54	68.1	-	-0.97
2026-01-06	DAWN	8.63	68.1	-	-0.97
2026-01-07	DAWN	9.61	68.1	-	-0.97
2026-01-08	DAWN	9.25	68.1	-	-0.97
2026-01-09	DAWN	8.93	65.7	-	-0.97
2026-01-12	DAWN	11.32	65.7	-	-0.97
2026-01-13	DAWN	10.59	65.7	-	-0.97
2026-01-14	DAWN	10.73	65.7	-	-0.97
2026-01-15	DAWN	10.50	65.7	-	-0.97
2026-01-16	DAWN	10.14	72.6	-	-0.97
2026-01-20	DAWN	12.11	72.6	-	-0.97
2026-01-21	DAWN	12.06	72.6	-	-0.97
2026-01-22	DAWN	12.33	72.6	-	-0.97
2026-01-23	DAWN	11.95	72.6	-	-0.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	DAWN	-0.19	-0.89	12.73
2025-12-29	DAWN	-0.19	-0.89	12.73
2025-12-30	DAWN	-0.19	-0.89	12.73
2025-12-31	DAWN	-0.19	-0.89	12.73
2026-01-02	DAWN	-0.19	-0.89	12.73
2026-01-05	DAWN	-0.19	-0.88	12.73
2026-01-06	DAWN	-0.19	-0.88	12.73
2026-01-07	DAWN	-0.19	-0.88	12.73
2026-01-08	DAWN	-0.19	-0.88	12.73
2026-01-09	DAWN	-0.19	-0.88	12.73
2026-01-12	DAWN	-0.18	-0.88	12.36
2026-01-13	DAWN	-0.19	-0.88	14.74
2026-01-14	DAWN	-0.19	-0.88	14.74
2026-01-15	DAWN	-0.19	-0.88	14.74
2026-01-16	DAWN	-0.19	-0.88	14.74
2026-01-20	DAWN	-0.19	-0.01	14.74
2026-01-21	DAWN	-0.19	-0.01	14.74
2026-01-22	DAWN	-0.19	-0.01	14.74
2026-01-23	DAWN	-0.19	-0.01	14.74
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.19

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-0.19

Institutional Transactions

-0.01

Beta

-1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

58.4

Max Drawdown 5-Year %

Target Price

23.56

P/E

Forward P/E

PEG

P/S

9.45

P/B

2.72

P/Free Cash Flow

EPS

-1.49

Average EPS Est. Cur. Y

-0.97

EPS Next Y. (Est.)

-0.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-113.53

Relative Volume

1.09

Return on Equity vs Sector %

-60.9

Return on Equity vs Industry %

-44.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

Day One Biopharmaceuticals, Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 184

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

stock quote shares DAWN – Day One Biopharmaceuticals, Inc. Stock Price stock today

news today DAWN – Day One Biopharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DAWN – Day One Biopharmaceuticals, Inc. yahoo finance google finance

stock history DAWN – Day One Biopharmaceuticals, Inc. invest stock market

stock prices DAWN premarket after hours

ticker DAWN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: DAWN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y